Q2 2026 saw strong growth in innovative and biosimilar portfolios, offset by a decline in generics and a significant one-time impact from the Emalex acquisition. Guidance for 2026 was reaffirmed, with raised outlooks for key innovative products and continued focus on margin expansion and debt reduction.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.